Evidence map›Paper›PMID 32461796›Full record

ArticleInternational journal of hematology-oncology and stem cell research2020

Treatment of Acute Lymphoid Leukemia Refractory to Classic First-Line and Rescue Protocols.

Flávia Tobaldini Russo, Maria Cristina Martins de Almeida Macedo, Pedro Amoedo Fernades, Larissa Yukari Okada, Lucas Augusto Monetta da Silva, Camila Menin Simões, Jamilla Neves Cavalcante, Aline de Almeida Simões, Manuella de Souza Sampaio Almeida, Maricy Almeida Viol Ferreira Lopes and 1 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC
In one paragraph

Article in International journal of hematology-oncology and stem cell research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Flávia Tobaldini RussoInstituto Brasileiro de Controle do Câncer (IBCC), São Paulo, Brazil.
Maria Cristina Martins de Almeida MacedoInstituto Brasileiro de Controle do Câncer (IBCC), São Paulo, Brazil.
Pedro Amoedo FernadesInstituto Brasileiro de Controle do Câncer (IBCC), São Paulo, Brazil.
Larissa Yukari OkadaInstituto Brasileiro de Controle do Câncer (IBCC), São Paulo, Brazil.
Lucas Augusto Monetta da SilvaFaculdade de Ciências Médicas Santa Casa de São Paulo, São Paulo, Brazil.
Camila Menin SimõesInstituto Brasileiro de Controle do Câncer (IBCC), São Paulo, Brazil.
Jamilla Neves CavalcanteInstituto Brasileiro de Controle do Câncer (IBCC), São Paulo, Brazil.
Aline de Almeida SimõesInstituto Brasileiro de Controle do Câncer (IBCC), São Paulo, Brazil.
Manuella de Souza Sampaio AlmeidaInstituto Brasileiro de Controle do Câncer (IBCC), São Paulo, Brazil.
Maricy Almeida Viol Ferreira LopesInstituto Brasileiro de Controle do Câncer (IBCC), São Paulo, Brazil.
Roberto Luiz da SilvaInstituto Brasileiro de Controle do Câncer (IBCC), São Paulo, Brazil.
Instituto Brasileiro de Controle do Câncer · BRFaculdade de Ciências Médicas da Santa Casa de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute Lymphoblastic Leukemia is a very aggressive malignant disorder of lymphoid cells in adults, with recurrence (30 to 60% of the cases) after the initial treatment. Until this moment, there is no gold standard therapy for the treatment of adult patients with acute relapsed/refractory lymphoblastic leukemia. In this case report, we describe two cases of relapsed leukemia: one of lymphocytic leukemia B and one of trilineage leukemia, which presented a satisfactory response to treatment with Bortezomib associated with Vincristine, Dexamethasone, and Bendamustine.

Indexed as

Acute lymphoblastic leukemiaLymphoid cellsRelapsed leukemia

Identifiers

PMID32461796
PMCPMC7231792
OpenAlexW3018693444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.